Compare Biocon Ltd with GSK Pharma - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

BIOCON vs GSK PHARMA - Comparison Results

BIOCON      Change

Biocon is India's largest biotechnology company with presence in biopharmaceuticals, custom research and clinical research. It started as an enzymes manufacturer and later evolved into an integrated biopharmaceutical company. The company has two subs... More

GSK PHARMA 
   Change

GSK Pharma is one of the leading MNC pharma companies in the Indian market. It is a 50.7% subsidiary of GlaxoSmithKline Plc, one of the world's largest pharma companies. GSK Pharma's product portfolio boasts of some of the leading brands like Augment... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    BIOCON GSK PHARMA BIOCON /
GSK PHARMA
 
P/E (TTM) x 22.8 32.3 70.4% View Chart
P/BV x 3.0 12.9 23.4% View Chart
Dividend Yield % 0.4 1.2 31.2%  

Financials

 BIOCON    GSK PHARMA
EQUITY SHARE DATA
    BIOCON
Mar-18
GSK PHARMA
Mar-19
BIOCON /
GSK PHARMA
5-Yr Chart
Click to enlarge
High Rs1,1883,595 33.0%   
Low Rs3051,253 24.3%   
Sales per share (Unadj.) Rs68.7184.7 37.2%  
Earnings per share (Unadj.) Rs7.626.3 28.7%  
Cash flow per share (Unadj.) Rs14.029.2 47.9%  
Dividends per share (Unadj.) Rs1.0020.00 5.0%  
Dividend yield (eoy) %0.10.8 16.2%  
Book value per share (Unadj.) Rs86.3126.3 68.4%  
Shares outstanding (eoy) m600.00169.40 354.2%   
Bonus/Rights/Conversions IS--  
Price / Sales ratio x10.913.1 82.7%   
Avg P/E ratio x98.992.2 107.2%  
P/CF ratio (eoy) x53.483.1 64.3%  
Price / Book Value ratio x8.619.2 45.1%  
Dividend payout %13.276.1 17.4%   
Avg Mkt Cap Rs m447,900410,626 109.1%   
No. of employees `0006.15.0 124.0%   
Total wages/salary Rs m9,3115,372 173.3%   
Avg. sales/employee Rs Th6,705.86,306.7 106.3%   
Avg. wages/employee Rs Th1,514.21,083.1 139.8%   
Avg. net profit/employee Rs Th736.9898.0 82.1%   
INCOME DATA
Net Sales Rs m41,23431,281 131.8%  
Other income Rs m2,0621,023 201.5%   
Total revenues Rs m43,29632,304 134.0%   
Gross profit Rs m8,2916,009 138.0%  
Depreciation Rs m3,851486 792.4%   
Interest Rs m6156 10,250.0%   
Profit before tax Rs m5,8876,540 90.0%   
Minority Interest Rs m2130-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m0287 0.0%   
Tax Rs m1,5692,373 66.1%   
Profit after tax Rs m4,5314,454 101.7%  
Gross profit margin %20.119.2 104.7%  
Effective tax rate %26.736.3 73.5%   
Net profit margin %11.014.2 77.2%  
BALANCE SHEET DATA
Current assets Rs m41,48620,061 206.8%   
Current liabilities Rs m21,41314,543 147.2%   
Net working cap to sales %48.717.6 276.0%  
Current ratio x1.91.4 140.5%  
Inventory Days Days6457 112.7%  
Debtors Days Days9414 669.8%  
Net fixed assets Rs m50,66114,343 353.2%   
Share capital Rs m3,0001,694 177.1%   
"Free" reserves Rs m48,80819,704 247.7%   
Net worth Rs m51,80821,398 242.1%   
Long term debt Rs m17,8982 894,900.0%   
Total assets Rs m99,89739,113 255.4%  
Interest coverage x10.61,091.0 1.0%   
Debt to equity ratio x0.30 369,621.1%  
Sales to assets ratio x0.40.8 51.6%   
Return on assets %5.211.4 45.2%  
Return on equity %8.720.8 42.0%  
Return on capital %9.631.9 30.2%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m12,058534 2,258.1%   
Fx outflow Rs m7,3487,091 103.6%   
Net fx Rs m4,710-6,557 -71.8%   
CASH FLOW
From Operations Rs m6,6213,994 165.8%  
From Investments Rs m-6,840-1,433 477.2%  
From Financial Activity Rs m-2,397-3,584 66.9%  
Net Cashflow Rs m-2,612-1,023 255.3%  

Share Holding

Indian Promoters % 40.4 0.0 -  
Foreign collaborators % 20.6 50.7 40.6%  
Indian inst/Mut Fund % 8.4 10.2 82.4%  
FIIs % 10.7 23.8 45.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 19.9 15.4 129.2%  
Shareholders   109,995 102,036 107.8%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare BIOCON With:   JUBILANT LIFE SCIENCES  DR. DATSONS LABS  WOCKHARDT  NOVARTIS  PANACEA BIOTECH  

Compare BIOCON With:   MYLAN (US)  ADCOCK INGRAM (S. Africa)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 72 Points Lower; Capital Goods and Auto Stocks Witness Selling(Closing)

India share markets witnessed selling pressure during closing hours and ended their day marginally lower.

Related Views on News

BIOCON Announces Quarterly Results (2QFY20); Net Profit Down 30.5% (Quarterly Result Update)

Nov 1, 2019 | Updated on Nov 1, 2019

For the quarter ended September 2019, BIOCON has posted a net profit of Rs 3 bn (down 30.5% YoY). Sales on the other hand came in at Rs 16 bn (up 19.0% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GSK PHARMA Announces Quarterly Results (2QFY20); Net Profit Up 398.9% (Quarterly Result Update)

Oct 25, 2019 | Updated on Oct 25, 2019

For the quarter ended September 2019, GSK PHARMA has posted a net profit of Rs 5 bn (up 398.9% YoY). Sales on the other hand came in at Rs 9 bn (up 8.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

BIOCON Announces Quarterly Results (1QFY20); Net Profit Down 11.5% (Quarterly Result Update)

Jul 29, 2019 | Updated on Jul 29, 2019

For the quarter ended June 2019, BIOCON has posted a net profit of Rs 1 bn (down 11.5% YoY). Sales on the other hand came in at Rs 5 bn (down 57.2% YoY). Read on for a complete analysis of BIOCON 's quarterly results.

GSK PHARMA Announces Quarterly Results (1QFY20); Net Profit Up 28.1% (Quarterly Result Update)

Jul 24, 2019 | Updated on Jul 24, 2019

For the quarter ended June 2019, GSK PHARMA has posted a net profit of Rs 1 bn (up 28.1% YoY). Sales on the other hand came in at Rs 8 bn (up 7.1% YoY). Read on for a complete analysis of GSK PHARMA's quarterly results.

GSK PHARMA 2018-19 Annual Report Analysis (Annual Result Update)

Jun 24, 2019 | Updated on Jun 24, 2019

Here's an analysis of the annual report of GSK PHARMA for 2018-19. It includes a full income statement, balance sheet and cash flow analysis of GSK PHARMA. Also includes updates on the valuation of GSK PHARMA.

More Views on News

Most Popular

Crash Alert! Is There a Big Bubble in Nestle, HUL and Asian Paints?(Profit Hunter)

Nov 7, 2019

Is this the beginning of the end of multibagger gains in quality stocks like Nestle, HUL, and Asian Paints?

Why Moody's Rating Downgrade is a Strong Sign to Buy Stocks(The 5 Minute Wrapup)

Nov 8, 2019

Investors who took cues from Moody's rating downgrade in 1992 and 2002 created some of the biggest wealth of their lifetime.

These 10 Days Are Crucial for Getting Rich in the Smallcap Rebound(Profit Hunter)

Nov 5, 2019

How to avoid the most common investing mistake and make the most of the smallcap rebound.

The Top Stocks for 2020 Pass This Most Critical Metric(The 5 Minute Wrapup)

Nov 5, 2019

Charlie Munger's favorite fictional character, Mr Glotz, picks stocks using this metric.

A Trade that Could Generate Profits for Decades

Nov 14, 2019

India's #1 trader is back on the Investor Hour. Vijay Bhambwani talks to us about his super-profitable trading system and shares with us his #1 long term trade. Listen in...

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

BIOCON SHARE PRICE


Nov 18, 2019 (Close)

TRACK BIOCON

COMPARE BIOCON WITH

MARKET STATS